Back to Search
JILL LEONARD, PHARM.D
PHARM.D
Pharmacist
NPI: 1326379025Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
052769(NY)
Research & Publications (20)
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
PMID 18853418·Cancer·2008
3-trial
Targeted treatment and new agents in diffuse large B-cell lymphoma.
PMID 18760704·Semin Hematol·2008
6-review
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
PMID 18567989·Clin Adv Hematol Oncol·2008
6-review
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
PMID 18349031·Ann Oncol·2008
8-other
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
PMID 17947483·Clin Cancer Res·2007
3-trial
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.
PMID 17530024·Oncogene·2007
6-review
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
PMID 17470451·Ann Oncol·2007
3-trial
Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
PMID 16557600·Int J Cancer·2006
6-review
Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
PMID 16304400·Hematology Am Soc Hematol Educ Program·2005
8-other
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
PMID 16110029·J Clin Oncol·2005
3-trial
New developments in immunotherapy for non-Hodgkin's lymphoma.
PMID 16091197·Curr Oncol Rep·2005
6-review
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
PMID 15955901·J Clin Oncol·2005
3-trial
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
PMID 15328168·Clin Cancer Res·2004
3-trial
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
PMID 12837807·J Clin Oncol·2003
3-trial
Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma.
PMID 12743990·Cancer Invest·2003
4-observational
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
PMID 11842393·Semin Oncol·2002
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 122 W 146TH ST
NEW YORK, NY 10039 - Phone
- (212) 675-3900
Quick Facts
- NPI
- 1326379025
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile